abstract |
Novel interleukin-20 (IL-20) binding molecules of human origin are provided, specifically human-derived anti-human IL-20 antibodies, IL-20 binding fragments, derivatives thereof and biotechnological variants. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described. In addition, cell-type enzyme-linked ligand-binding assays isolate recombinant human-derived anti-human cytokine antibodies specifically to isolate antibodies and their biotechnological derivatives for pharmaceutical use To be described. |